CoChat
Sign Up
Cited by 238

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands

Pijlman, A.H., Huijgen, R., Verhagen, S.N., Imholz, B.P.M., Liem, A.H., Kastelein, J.J.P., Abbink, E.J., Stalenhoef, A.F.H., Visseren, F.L.J.·2010·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2009.09.014
Open this paper in CoChat — free account

Abstract

Background Heterozygous familial hypercholesterolemia (heFH) is a common autosomal dominant hereditary disorder caused by mutations in the LDL-receptor gene that lead to elevated plasma levels of low-density lipoprotein-cholesterol (LDL-c). Robust lowering of LDL-c levels is essential for risk reduction of premature cardiovascular diseases and early death. European and Dutch guidelines recommend to treat LDL-c to plasma levels Methods A cross-sectional study was conducted in outpatient lipid clinics of three Academic Centers and two regional hospitals. Patient records of known heFH patients were retrieved and data were reviewed on the use of lipid-lowering medication, plasma lipids and lipoproteins, safety laboratory results and reasons for not achieving treatment goals. Results The data of 1249 patients with heFH were available. Nearly all patients (96%) were on statin treatment. The treatment goal for LDL-c or=2.5mmol/l, was acceptance of a higher target LDL-c level by the treating physician. An alternative treatment goal of >50% LDL-c reduction, as recommended in the NICE guidelines, was achieved in 47% of patients with an LDL-c >or=2.5mmol/l and not using maximum therapy. Conclusion Only a small proportion of patients with heFH reaches the LDL-c treatment target of <2.5mmol/l. These results emphasize the need for better monitoring, better utilization of available medication and for new treatment options in heFH to further decrease LDL-c levels.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2009.09.014

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current hypercholesterolaemia treatments can be insufficient in restoring plasma cholesterol levels to within a normal physiological range.

    “Despite their clinical success in the majority of individuals, these treatments can be insufficient in restoring plasma cholesterol levels to within a normal physiological range [12].”

    From Post-translational regulation of the low-density lipoprotein receptor provides new targets for cholesterol regulation (2024) · cites this paper as [12]

  • Despite large clinical success, current lipid-lowering treatments do not always restore plasma cholesterol levels to within a normal physiological range and can increase the risk of developing other diseases such as type 2 diabetes.

    “Despite their large clinical success, these treatments do not always restore plasma cholesterol levels to within a normal physiological range8 and can increase the risk of developing other diseases such as type 2 diabetes9.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [8]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. 1991, BMJ, 303, 893, 10.1136/bmj.303.6807.893 · DOI · Paper page
  2. Wiegman, 2004, Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia, Lancet, 363, 369, 10.1016/S0140-6736(04)15467-6 · DOI
  3. Austin, 2004, Familial hypercholesterolemia and coronary heart disease: a HuGE association review, Am J Epidemiol, 160, 421, 10.1093/aje/kwh237 · DOI
  4. 1999, Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management, Atherosclerosis, 142, 105, 10.1016/S0021-9150(98)00200-7 · DOI
  5. Rodenburg, 2007, Statin treatment in children with familial hypercholesterolemia: the younger, the better, Circulation, 116, 664, 10.1161/CIRCULATIONAHA.106.671016 · DOI
  6. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25):3143–421. · DOI · Paper page
  7. De Backer, 2003, Eur J Cardiovasc Prev Rehabil, 10, S1, 10.1097/00149831-200308000-00004 · DOI
  8. Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 · DOI · Paper page
  9. Alonso, 2001, Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin, Atherosclerosis, 157, 423, 10.1016/S0021-9150(00)00733-4 · DOI
  10. Kane, 1990, Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens, JAMA, 264, 3007, 10.1001/jama.1990.03450230043027 · DOI
  11. Kroon, 1996, LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis, Circulation, 93, 1826, 10.1161/01.CIR.93.10.1826 · DOI
  12. Smilde, 2001, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, Lancet, 357, 577, 10.1016/S0140-6736(00)04053-8 · DOI
  13. Wierzbicki, 2008, Familial hypercholesterolaemia: summary of NICE guidance, BMJ, 337, a1095, 10.1136/bmj.a1095 · DOI
  14. Walma, 2006, The practice guideline ‘Diagnosis and treatment of familial hypercholesterolaemia’ of the Dutch Health Care Insurance Board, Ned Tijdschr Geneeskd, 150, 18
  15. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
  16. Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA, 291, 1071, 10.1001/jama.291.9.1071 · DOI
  17. Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437 · DOI · Paper page
  18. Kastelein, 2008, Simvastatin with or without ezetimibe in familial hypercholesterolemia, N Engl J Med, 358, 1431, 10.1056/NEJMoa0800742 · DOI · Paper page
  19. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events. Eur Heart J 1997;18(10):1569–82. · DOI
  20. Kotseva, 2008, Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey, Atherosclerosis, 197, 710, 10.1016/j.atherosclerosis.2007.07.004 · DOI
  21. Hadfield, 2008, Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project, Ann Clin Biochem, 45, 199, 10.1258/acb.2007.007078 · DOI
  22. Versmissen, 2008, Efficacy of statins in familial hypercholesterolaemia: a long term cohort study, BMJ, 337, a2423, 10.1136/bmj.a2423 · DOI
  23. Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423 · DOI · Paper page
  24. Davidson, 2002, Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia, J Am Coll Cardiol, 40, 2125, 10.1016/S0735-1097(02)02610-4 · DOI
  25. Florentin, 2008, Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia, Curr Med Res Opin, 24, 995, 10.1185/030079908X280446 · DOI

Cited by

Sorted by citations

Metadata

Authors
Pijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P. M., Liem, A. H., Kastelein, J. J. P., Abbink, E. J., Stalenhoef, A. F. H., & Visseren, F. L. J.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2010-03
Volume
209
Issue
1
Pages
189-194
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2009.09.014
Cited by
238
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review